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Abstract 
Preclinical studies demonstrate that pro-inflammatory cytokines increase 
serotonin transporter availability and function, leading to depressive 
symptoms in rodent models. Herein we investigate associations between 
circulating inflammatory markers and brainstem serotonin transporter (5-
HTT) availability in humans. We hypothesised that higher circulating 
inflammatory cytokine concentrations, particularly of tumour necrosis factor 
(TNF-α), would be associated with greater 5-HTT availability, and that TNF-
α inhibition with etanercept (sTNFR:Fc) would in turn reduce 5-HTT 
availability. In 13 neurologically healthy adult women, plasma TNF-α 
correlated significantly with 5-HTT availability (rho=0.6; p=0.03) determined 
by [123I] -beta-CIT SPECT scanning. This association was replicated in an 
independent sample of 12 patients with psoriasis/psoriatic arthritis 
(rho=0.76; p=0.003). Indirect effects analysis, showed that there was a 
significant overlap in the variance explained by 5-HTT availability and TNF-α 
concentrations on BDI scores. Treatment with etanercept for 6-8 weeks was 
associated with a significant reduction in 5-HTT availability (Z= 2.09 ; 
p=0.03; r=0.6) consistent with a functional link. Our findings confirm an 
association between TNF-α and 5-HTT in both the basal physiological and 
pathological condition. Modulation of both TNF-α and 5-HTT by etanercept   
indicate the presence of a mechanistic pathway whereby circulating 
inflammatory cytokines are related to central nervous system substrates 
underlying major depression.  
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Introduction 
Studies over the last few decades have found a strong link between 
inflammatory processes and psychiatric illnesses, particularly major 
depressive disorder (MDD).  At least three meta-analyses have confirmed the 
presence of greater circulating inflammatory marker levels in major 
depressive disorder (Dowlati et al., 2010; Howren et al., 2009; Liu et al., 
2012). Greater circulating inflammatory marker levels have been found to 
predict the development of MDD in longitudinal studies (Valkanova et al., 
2013).  Among medically ill, those with inflammatory diseases are at greater 
risk of developing a major depressive illness (Kurd et al., 2010). 
While the above findings are essentially correlational, a causal link has been 
proposed by findings that patients treated with cytokines for illnesses like 
hepatitis C, are at greater risk of developing a major depressive 
illness(Loftis et al., 2013; Myint et al., 2009).  Conversely, biological anti-
inflammatory agents, that target proinflammatory cytokines in a highly 
specific manner, induce an antidepressant  effect in patients, independent 
of improvement in the inflammatory condition (Feldmann and Maini, 2001, 
2003, 2010; Feldmann et al., 2010; Tyring et al., 2006). Given these clinical 
observations, it is proposed that the immune system and inflammation may 
play a role in the aetiopathogenesis of MDD (Dantzer et al., 2008; Kelley et 
al., 2003; Krishnadas and Cavanagh, 2012; Raison et al., 2006; Smith, 1991; 
Stein et al., 1991).  
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When exploring the pathophysiological underpinnings of depression, the 
monoamine neurotransmitter systems remain a central and translationally 
relevant biological substrate (Schildkraut, 1965).  
Among the monoamines, the serotonergic system  modulates emotional 
regulation, reward and punishment processing, behavioural inhibition, delay 
discounting and has been implicated in the aetiopathogenesis of MDD (Cools 
et al., 2008; Massart et al., 2012; Schildkraut, 1965) [see (Albert and 
Benkelfat, 2013; Albert et al., 2012) for a special issue on an update on the 
serotonin hypothesis in the neurobiology of depression] . The mesencephalic 
rostral raphe nuclei (including the median and dorsal raphe) account for 85% 
of all serotonergic neurons in the brain. They innervate the cerebral cortex 
and the limbic forebrain, including the hypothalamus, hippocampus and 
amygdala and receive descending projections from the limbic forebrain and 
ascending projections from the periaqueductal grey matter(Descarries et 
al., 2010). The serotonin transporter (5-HTT) plays an essential role in 
serotonin neurotransmission, by regulating synaptic serotonin levels. They 
are not only present in the projection areas on the neuronal presynaptic cell 
membrane, but also on cell bodies within the raphe nuclei distributed near 
the midline of the brainstem (Canli and Lesch, 2007; Descarries et al., 2010; 
Hornung, 2003; Maximino, 2012). In vitro studies confirm a significant 
correlation between 5-HTT levels and tissue concentrations of serotonin, 
suggesting that the former is a proxy marker for serotonin in healthy 
brain(Dewar et al., 1991). Depressive symptoms in humans have been 
associated with increased availability/function of 5-HTT, pointing to a 
reduction in synaptic serotonin levels (Meyer, 2008; Savitz and Drevets, 
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2013). While the monoamine hypothesis by itself is far from complete in 
explaining the pathophysiology underlying depression, a majority of 
available antidepressants inhibit 5-HTT at therapeutic doses and promote an 
increase in synaptic serotonin (Meyer, 2012).   
 
The serotonergic neurotransmitter system is a prime candidate to explore 
the link between inflammation and the aetiopathogenesis of MDD. This 
potential link is supported by findings from preclinical studies in rodent 
models that directly link proinflammatory cytokines with brain 5-HTT 
availability through activation of MAPK pathways (Baganz and Blakely, 2013; 
Couch et al., 2013; Katafuchi et al., 2006; Malynn et al., 2013; Morikawa et 
al., 1998; Ramamoorthy et al., 1995; Samuvel, 2005; Tsao et al., 2008). 
There are number of pathways through which circulating inflammatory 
markers can signal the brain including active transport across the blood-
brain barrier (BBB); second messenger signals from the endothelial lining of 
BBB;  through afferent vagal pathways; passage of cytokines through ‘leaky’ 
regions in the BBB(Capuron and Miller, 2011). Of particular theoretical 
relevance is that, in humans, the raphe nuclei (dorsal) are located close to 
the cerebral aqueduct making it particularly vulnerable to inflammatory 
signalling molecules present in the cerebral spinal fluid (CSF) (Howerton et 
al., 2014). They are also highly connected with humoral sensing 
circumventricular organs like the subfornical organ, which have fenestrated 
capillaries that allow exposure to large molecules like inflammatory 
cytokines, and form part of the key viscerosensory paths in the 
brain(Critchley and Harrison, 2013; Wallacelind, 1986).  
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No human studies have examined the association between circulating 
inflammatory markers and brainstem 5-HTT availability.  Herein, we 
addressed two key questions. Firstly, is there a relationship between 
circulating inflammatory markers and 5-HTT in humans?  And secondly, will 
highly specific cytokine inhibition result in changes in 5-HTT availability? 
Thus, we explored the association between circulating inflammatory 
markers and brainstem 5-HTT availability in a cohort of neurologically 
healthy volunteers and replicated our finding in a cohort of patients with 
psoriasis / psoriatic arthritis. We also ascertained whether administration of 
etanercept (TNF receptor:Fc fusion protein) would be associated with 
changes in serotonin transporter availability. In keeping with preclinical 
studies, we hypothesised that greater pro-inflammatory cytokine 
concentrations would be associated with greater 5-HTT availability in the 
brain, and that treatment with etanercept would be associated with a 
reduction in 5-HTT availability.  
 
Materials and Methods  
Study design 
The study was approved by the West of Scotland Research ethics committee 
and the Administration of Radioactive Substances Advisory Committee. All 
participants gave written informed consent. The study was conducted on 
two independent groups of subjects  
 
 
  
   7 
 
Healthy subjects: 
Firstly, we explored the association between, circulating inflammatory 
markers and brainstem 5-HTT availability in a group of healthy adult 
subjects (Figure 1a). Circulating inflammatory marker concentrations and 5-
HTT availability data were obtained from thirteen healthy menopausal 
women who were non-smokers, non-hypertensive, non-diabetic and not 
taking any drugs which could affect vascular function, and not being 
prescribed antidepressant medications or hormone replacement treatment. 
Data from this sample exploring a different hypothesis has been published 
previously as part of another study (Sassarini et al., 2014).  
Psoriasis/ psoriatic arthritis subjects: 
We then replicated this association in a group of patients with 
psoriasis/psoriatic arthritis. Fifteen subjects diagnosed with 
psoriasis/psoriatic arthritis aged 30-65 years, were recruited into the study. 
Three patients dropped out - one withdrew consent, and the other two had 
incidental findings on the MRI. Therefore, data from 12 individuals were 
analysed. All patients met disease activity criteria set by NICE pertaining to 
the use of Etanercept for psoriasis and psoriatic arthritis, and had been 
previously treated with a disease modifying agent (methotrexate) for at 
least 6-8 weeks. Those who incidentally fulfilled the criteria for MDD were 
included in the study. However, those with a history of antidepressant 
intake in the previous 3 months; history of cerebrovascular disease, 
documented head trauma or neurological disorders, lifetime history of DSM 
Axis I psychiatric diagnoses other than depression (measured using SCID), 
alcohol and/or substance misuse, pregnancy, other connective tissue or 
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systemic inflammatory disease were excluded from participation. None of 
the patients fulfilled a SCID diagnosis for a DSM IV Axis 1 psychiatric 
disorder, and none of them were started on an antidepressant during the 
study. 
Finally, in order to examine if highly specific TNF inhibition would alter 5-
HTT availability, we compared 5-HTT availability, before and after 
treatment with etanercept for 6 - 8 weeks (Figure 1b). Etanercept is a 
recombinant human TNF-α receptor fusion protein with 934 aminoacids and 
weighs 150kDa (Strober et al., 2008; Tan et al., 2007). It binds to TNF-α, 
thereby blocking its interaction with cell-surface receptors (Feldmann and 
Maini, 2001, 2010). Etanercept is licensed for use in adults with active 
psoriasis/ psoriatic arthritis (Fantuzzi et al., 2008). The administration of 
etanercept provided a molecular scalpel to interrogate the functional 
implications of the elevated TNF levels (and consequent inflammation) 
present in patients with psoriasis / psoriatic arthritis. The required sample 
size was calculated based on a pilot study by Cavanagh et al(Cavanagh et 
al., 2010). In order to demonstrate a reduction in 5-HTT availability with an 
effect size of d=1.2, with 80% power, with an alpha of 0.05, the total 
sample size required was 10 subjects.  
 Inflammatory markers  
The levels of 5 circulating inflammatory markers (from the meta-analyses of 
inflammatory markers in depression) were measured from plasma(Dowlati et 
al., 2010; Howren et al., 2009; Liu et al., 2012) extracted on the same day 
as the SPECT scans, just before the administration of the ligand. Blood (10 
mL) was drawn into BD Vacutainer System tubes (BD Diagnostics, 
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Perianalytical Systems, Oxford) containing ethylenediamine tetraacetic acid 
(EDTA) anticoagulant and centrifuged immediately at 3000rpm for 10 min. 
Plasma was extracted, and frozen at −80°C before analysis.   Cytokines 
were measured in duplicates using sandwich immunoassays, with all samples 
from the same volunteer on the same plate. They included TNF-α, IL-1b and 
IL-6 (Ready-set-go ELISAs, eBioscience, UK); sIL-2R (Platinum ELISA, 
eBioscience, UK) and hsCRP (ELISA, Invitron, UK).  The sensitivity, intra- and 
inter-assay coefficient of variations, are shown in table 2 (supplemental 
materials).  Two out of 13 healthy subjects had non-detectable levels of 
plasma TNF-α. For non-detectable values, we imputed the data using  half 
the limit of detection (LOD/2) as suggested by Hornung et al (Hornung and 
Reed, 1990). Since most of the data was missing (11 out of 13), we did not 
analyse the relationship between IL6 and 5-HTT in healthy subjects. 
 
Beck's depression inventory (BDI II) (Beck et al., 1996) 
Beck's depression inventory II is a 21 item self-rated Likert-scale 
questionnaire that measures depressive symptoms over the past 2 weeks. 
Each question is scored on a scale of 0 to 3 yielding a total score ranging 
from 0 to 63, with higher scores indicating greater depressive symptoms.  
The scale was administered on the same day as the SPECT scans. 
 
[123I] -beta-CIT SPECT measurement of 5-HTT availability 
All participants underwent a [123I] -beta-CIT SPECT scan to ascertain 
brainstem 5-HTT availability. Those with psoriasis/arthritis underwent the 
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scan at least 14 days before and again 6 - 8 weeks after the commencement 
of weekly etanercept 50mg administered subcutaneously.  
The SPECT imaging protocol has been validated and described in detail in 
the past (Cavanagh et al., 2006). Briefly, brain SPECT imaging was 
performed with a dedicated state of the art, 12 headed Neurofocus 900 
SPECT scanner (spatial resolution 7mm full width at half maximum with a 
line source in air; NeuroPhysics, Shirley, Massachusetts), which acquires 
sequential single transaxial brain sections (see figure 4). Taking advantage 
of its pharmacokinetic properties, brainstem and diencephalon [123I] -beta-
CIT  uptake at 3 -4 hours was used to quantify 5-HTT availability as proposed 
by de Win et al (de Win et al., 2005b). Details of acquisition and [123I] -beta-
CIT are given in the supplemental material. 
 
Radioligand [123I] -beta-CIT preparation for the study 
[123I] -beta-CIT was prepared via electrophilic iododestannylation of the 
corresponding tributylstannyl precursor (Baldwin et al., 1993).  Briefly, 
reagents were added to carrier free Na123I (370-740 MBq) in approximately 
10-20 µl of 0.05 M NaOH, in the following order: 30 µg tributylstannyl 
precursor in 300 µl glacial acetic acid followed by 10% V/V peracetic acid. 
The reaction proceeded for 20 minutes at room temperature. 500 µl of 
NaOH was then added. The mixture was purified by reverse-phase HPLC and 
the solvent removed by rotary evaporation. The [123I] -beta-CIT was 
formulated as 150 MBq in 5 ml ≤6% ethanol in isotonic citrate acetate buffer 
and filtered through a 0.22 µm filter. The [123I] -beta-CIT was produced with 
  
   11 
 
an isolated radiochemical yield of 69.6 ± 8.9 % (n = 29). Pyrogenicity tests 
and sterility tests were performed.   
 
SPECT Imaging 
The SPECT imaging protocol has been validated and described in detail in 
the past (Cavanagh et al., 2006).  [123I] -beta-CIT binds with high affinity in 
vitro to both dopamine transporter (DAT) and 5-HTT.  In vivo studies in both 
humans and nonhuman primates have shown that [123I] -beta-CIT 
accumulates in two distinct brain regions.  In the striatum, where the 
density of DAT is much higher than that of 5-HTT, [123I] -beta-CIT binding 
mainly reflects DAT density, whereas in the brainstem and diencephalon 
binding seems to be specific for 5-HTT. The kinetics of [123I] -beta-CIT 
binding differs markedly between the DAT-rich and 5-HTT-rich regions.  The 
slow uptake in the striatum, which reaches a peak after 20-30 hours, is in 
contrast to the faster kinetics seen in the brainstem and the diencephalon, 
where peak activity is attained after 2-4 hours after administration.  In this 
study, early imaging of 5-HTT regions was performed to minimize any 
possible effect of DAT on the 5-HTT measurement because DAT uptake is 
proportionally lower at 3 hours (de Win et al., 2005a). 
Brain SPECT imaging was performed with a dedicated state of the art, 12 
headed Neurofocus 900 SPECT scanner (spatial resolution 7mm full width at 
half maximum with a line source in air; NeuroPhysics, Shirley, 
Massachusetts), which acquires sequential single transaxial brain sections.  
Up to 25 axial sections 6 mm apart were scanned and the energy window 
(140-178 keV) was placed symmetrically around the 123I gamma energy of 
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159 keV.  A linear attenuation correction was applied, based on an 
automatically detected ellipse matching the outer head surface. As 
proposed by de Win et al, subjects were scanned starting 3 – 4 hours after IV 
administration of [123I] -beta-CIT in order to establish uptake in 5-HTT rich 
areas (de Win et al., 2005a).  To minimize thyroid uptake of radioactive 
iodine, 120mg of potassium iodide was administered orally to each subject 
at least one hour prior to [123I] -beta-CIT injection.  Scanning time was 
approximately 50 min per scan. 
 
Regions of Interest analysis 
Region of interest (ROI) analysis was carried out by an investigator (AN) 
blinded to the subject’s clinical and demographic history.  A standard ROI 
template was constructed with the aid of two image templates: (1) the 
standard magnetic resonance imaging template known as ICBM152, which is 
based on 152 normal MRI scans and is available from the Statistical 
Parametric Mapping web site of the Functional Imaging Laboratory 
(http://www.fil.ion.ucl.uk/spm/); and (2) and in-house cerebral perfusion 
template based on 32 normal SPECT scans of cerebral perfusion. 
The ROI template consisted of manually drawn regions representing the 
brain stem/diencephalon ROI (referred to as the brain stem ROI below for 
brevity), and a reference ROI.  The brain stem ROI (23 cm3) was drawn on 
seven axial sections 5mm apart and comprised the thalamus-hypothalamus, 
mid-brain, and pons.  In order to see if the [123I] -beta-CIT uptake is specific 
to 5-HTT and not to DAT we estimated [123I] -beta-CIT uptake in the 
striatum. The striatum ROI (7.6 cm3 on each side) was drawn on three axial 
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sections 5 mm apart and encompassed the head of caudate and putamen in 
both hemispheres. The reference ROI (35 cm3) was drawn on three axial 
sections 5 mm apart in the medial and lateral occipital lobe bilaterally.  The 
occipital region was chosen to represent nonspecific and non-displaceable 
[123I] -beta-CIT uptake (i.e., signal not associated with binding to 
transporters) because it has a negligible density of serotonin transporters. 
The [123I] -beta-CIT uptake in each ROI was expressed as mean counts per 
pixel, and the specific uptake of [123I] -beta-CIT was calculated as:  
 
			
		ℎ			 − 		
		ℎ	
	 
 
Binding potential quantifies the equilibrium concentration of specific 
binding as a ratio to a reference concentration. As defined by Innis et al, 
BPND refers to the ratio at equilibrium of specifically bound radioligand to 
that of non-displaceable radioligand in tissue(Innis et al., 2007). BPND for 5-
HTT was then defined as the ratio of specific uptake to uptake in the 
occipital reference region using the formula:   
 
 =
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Under equilibrium conditions the binding ratio is proportional to transporter 
binding potential (BPND). Provided transporter affinity and nonspecific 
binding are invariant across subjects, the ratio is then a measure of 
transporter availability.  
Statistical analysis 
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Given the small sample size, non-parametric tests were performed wherever 
possible in IBM SPSS Statistics version 19(IBMCorp, 2011). Differences 
between two independent groups were tested using Mann Whitney U Test. 
Differences between dependent variables were tested using Wilcoxon 
signed-rank test. Spearman’s correlation was used to explore the 
relationship between inflammatory markers and 5-HTT.  
To explore the relationship between TNF-α, 5-HTT (BPND) and BDI scores, we 
conducted an "indirect effects" analysis with TNF-α levels as independent 
variable, 5-HTT as the "indirect variable" and BDI scores as dependent 
variable. For this analysis, we combined the data from the healthy controls 
and the patient population. Details of the calculation are in the 
supplemental material. Briefly,  we aimed to examine if a proportion of 
variance in 5-HTT could explain the relationship between TNF-α levels and 
BDI scores. "This analysis differs from multiple regression which estimates 
the proportion of variance in the dependent variable accounted for by each 
of several independent predictor variables while allowing for the variance 
accounted for by the other predictors in the model.”(Palaniyappan and 
Liddle, 2012) This analysis is similar to classic mediation analysis. While 
mediation analysis typically assume causal interactions, it should be noted 
that causal assumptions are not made here as the cytokine, 5-HTT and BDI 
were measured simultaneously. We therefore use the term  "indirect effects 
analysis" as recommended by Preacher and Hayes (Preacher and Hayes, 
2008). The indirect effects analysis partitions the variance explained by the 
independent  into i) a part that is independent of the indirect variable, and 
ii) a part that is accounted for via the indirect variable. We used the 
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bootstrap method of Preacher and Hayes to estimate the bias-corrected 95% 
confidence interval (CI) of the "indirect effect" based on 20,000 bootstrap 
samples using an SPSS macro (indirect)(Preacher and Hayes, 2008). This 
analysis requires no assumption regarding the underlying distributions since 
the statistical significance level is determined non-parametrically. All p 
values mentioned are two-tailed. 
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Results 
Circulating TNF-α concentrations correlated with brainstem 5-HTT 
availability in healthy adults  
This analysis was conducted on data from the thirteen healthy volunteers 
(mean age = 57 years). As age correlated with 5-HTT availability (rho=-0.52; 
p=0.08),  5-HTT availability was corrected for age in order to maximise the 
variance explained by TNF-α. Plasma TNF-α showed a significant positive 
correlation with brainstem 5-HTT availability (corrected for age) (n=13; 
Spearman's rho=0.6; p=0.03) (figure 2.a).  None of the other inflammatory 
markers showed a statistically significant correlation with 5HTT availability 
(figures 2 b-d).  
Circulating TNF-α concentrations correlated with brainstem 5-HTT 
availability in psoriasis/psoriatic arthritis 
This analysis was conducted on data from twelve patients [6 males and 6 
females (mean age = 47.58; s.d.=8.8)] with psoriasis/psoriatic arthritis.  The 
5-HTT availability was corrected for age, sex and diagnosis 
(psoriasis/psoriatic arthritis). Plasma TNF-α showed a significant positive 
correlation with 5-HTT availability (n=12; Spearman's rho=0.76; p=0.004) 
(figure 2.e).None of the other circulating inflammatory markers showed a 
statistically significant correlation with 5-HTT availability (figures 2 f - i).  
Although brainstem [123I] -beta-CIT uptake at 3-4 hours has been attributed 
to 5-HTT availability, it has been proposed [123I] -beta-CIT uptake in the 
narrow brain regions that span between the midbrain periaqueductal area 
and substantia nigra may also represent DAT uptake(Laruelle et al., 1993).  
We therefore examined if the association was specific to 5-HTT. We used 
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striatal [123I] -beta-CIT uptake at 24 hours as a measure of DAT specific 
binding from 11 participants from the psoriasis group. We found some non-
significant correlation between 5-HTT and DAT (rho=0.39;p=0.26). However, 
there was no correlation between TNF-α and striatal DAT availability (rho=-
0.042;p=0.9). In addition, the correlation between TNF-α and 5-HTT 
improved after controlling for DAT availability (rho=0.92;p<0.001), 
suggesting that the correlation between TNF-α and midbrain [123I] -beta-CIT 
binding index may be 5-HTT specific. 
 
TNF-α has an indirect effect on depression scores, through brainstem 5-
HTT availability 
The indirect effects analysis examined if the variance explained by the 5-
HTT availability and TNF concentrations on BDI scores overlapped. Figure 3 
shows that 5-HTT availability had a significant indirect effect on the 
relationship between circulating TNF-α and BDI scores (Indirect effect: 
β=0.37; SE =0.24; 95% CI = 0.02 to 1.16). In other words, there was a 
significant overlap in the variance explained by 5-HTT and TNF 
concentrations on BDI. 
Specific TNF-α inhibition was associated with a reduction in 5-HTT 
availability 
Psoriasis/ psoriatic arthritis participants received etanercept for an average 
6.58 weeks (s.d. = 0.79). There was no significant difference in the dose of 
[123I] -beta-CIT at baseline (average dose = 150.08 MBq) and post-treatment 
scans (average dose = 148.5 MBq) (Z=-0.92;p=0.36). A Wilcoxon Signed-ranks 
test indicated that 5-HTT availability decreased following etanercept 
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treatment (Z= 2.09 ; p=0.03; r=0.6) (Figure 4) consistent with a functionally 
meaningful relationship between TNF-α, or its downstream effector 
pathways and 5-HTT expression in humans. As expected, hsCRP 
(Z=2.59;p=0.009; r=0.75) and IL6 (Z=2.36;p=0.02;r=0.68) showed a 
significant decrease with treatment.  As previously reported, TNF levels 
increased following treatment with etanercept (Z=2.70;p=0.007;r=0.78), 
reflecting an increase in bound TNF to the fusion protein that is detected by 
the ELISA(Bhatia and Kast, 2007; Kotyla et al., 2015).  BDI scores also 
showed a reduction following treatment with etanercept 
(Z=2.2;p=0.03;r=0.63) (Table 1). We found no association between change in 
CRP levels and change in BDI (rho=-0.15;p=0.6) and change in 5-HTT 
(rho=0.014;p=0.9).  
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Discussion 
We examined the relationship between circulating inflammatory markers 
and brainstem 5-HTT availability - a biological substrate of mood regulation. 
For the first time in two independent human samples, we have established 
an association between circulating TNF-α and 5-HTT availability (brainstem 
[123I] -beta-CIT uptake). Circulating TNF-α showed a strong positive 
correlation with 5-HTT availability in both a basal physiologic state, with 
low circulating cytokine concentrations and a pathological state with high 
circulating cytokines concentrations. We found no association between TNF-
α and DAT availability (striatal [123I] -beta-CIT uptake). In addition, 
controlling for any striatal uptake (representative of DAT availability) 
increased the correlation between TNF-α and brainstem uptake, suggesting 
that the association is driven by 5-HTT and not DAT availability.  
We chose a sample of patients with psoriasis for two reasons. Firstly, this is 
a condition where inflammation is fundamental in its pathophysiology and 
depression is highly prevalent (Coimbra et al., 2012; Gladman et al., 2005; 
Hayes and Koo, 2010; Kurd et al., 2010; Nestle et al., 2009; Schmitt and 
Ford, 2007). Secondly, this population gave us the ideal opportunity to 
explore the effect of TNF antagonism on 5-HTT. Earlier research in this 
population has shown that TNF antagonism was associated with an 
antidepressant effect that was independent of disease improvement 
(Gelfand et al., 2008; Krishnan et al., 2007; Langley et al., 2010; Tyring et 
al., 2006).  Consistent with previous studies, TNF-α explained only around 
3% of and brain stem 5-HTT availability explained only around 7% variance in 
depression severity (Gryglewski et al., 2014; Valkanova et al., 2013). 
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However the relationship between TNF-α and BDI scores was explained at 
least in part by an indirect effect through 5-HTT availability, suggesting that 
our findings are behaviourally relevant (Valkanova et al., 2013). Crucially, 
we replicated our previous findings that highly specific TNF-α inhibition was 
associated with a significant reduction in brainstem 5-HTT availability 
(Cavanagh et al., 2010).   Since etanercept does not cross BBB it is likely 
that modulation of circulating inflammatory markers was responsible for the 
changes (Krishnadas, 2010).  While it is possible that the reduction in 5-HTT 
availability was the result of improvement in clinical symptoms of 
psoriasis/arthritis, reduction in CRP - a marker of clinical inflammatory 
activity - was not associated with the reduction in 5-HTT (Beygi et al., 2013; 
Coimbra et al., 2009; Strober et al., 2008). In addition, clinical response 
rates to etanercept are around 50% and peak at 4 to 6 months following 
therapy. We examined our participants 6-8 weeks following treatment with 
etanercept. Our findings are consistent with clinical studies that have shown 
a hedonic effect of etanercept that precedes clinical improvement of 
psoriasis (Tyring et al., 2006). 
Our findings are in keeping with preclinical studies that have shown  
an association between TNF-α and 5-HTT. TNF-α treatment is associated 
with increases in MAPK-dependent 5-HTT uptake capacity, maximum uptake 
velocity and mRNA expression (Malynn et al., 2013; Mossner et al., 1998; 
Zhu et al., 2006). These changes have been associated with behaviour 
consistent with 'sickness behaviour' in rodent models (Zhu et al., 2010). [123I] 
-beta-CIT uptake does not differentiate between changes 5-HTT affinity to 
its ligands, 5-HTT density on the cell surface, or serotonergic neuronal 
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numbers.  While it could be argued that at least some of 5-HTT activity is 
dependent on its cell-surface density, there clearly exist mechanisms by 
which synaptic serotonin is controlled by mechanisms independent of 
transporter numbers. In this context, it should be noted that [123I] –beta-CIT 
uptake also does not differentiate glial and neuronal 5-HTT availability. In 
contrast to previous studies, we did not find any correlation between other 
circulating inflammatory markers and brainstem 5-HTT availability 
(Ramamoorthy et al., 1995). Since we did not measure central cytokine 
concentrations, it is not possible to infer if circulating TNF levels reflects 
central levels. While it is known that TNF is produced in the central nervous 
system (CNS) by astrocytes, microglia and certain neurons, CSF levels of TNF 
have been found to be significantly lower than plasma levels(Ellison et al., 
2005; Lampa et al., 2012).  At physiological conditions, the presence of 
soluble and cell bound TNF-α in the brain, makes it difficult to estimate CSF 
TNF-α levels reliably.  Interestingly, in our sample, circulating TNF-α level 
did not correlate significantly with other pro-inflammatory cytokines 
suggesting TNF-α explain significant variance in 5-HTT that is independent 
of other cytokines (Supplemental tables 3 &4).  Many factors will regulate 
their measurable concentrations of cytokine in serum or plasma including 
synthesis rate, renal clearance, presence of soluble neutralising receptors 
etc.  Thus we would not have expected direct correlations between cytokine 
measures.  IL-6 levels correlated with to CRP (rho=0.68;p=0.01) given the 
rather direct role it has in driving hepatocyte acute phase reactant 
synthesis. However, it is unclear if this lack of correlation between 
inflammatory markers was reflected centrally. Previous research has shown 
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that relationship between TNF and other cytokines differ in the periphery 
and the CNS (Skelly et al., 2013). In addition, we restricted our analysis to 
those cytokines that have shown significant elevation in depressive illnesses. 
Previous studies have found a significant association between other 
inflammatory markers (that we did not explore), including IFN α, γ and 5-
HTT in animal models (Katafuchi et al., 2006; Morikawa et al., 1998; Tsao et 
al., 2008).  
So, can circulating inflammation have an effect centrally? Circulating 
inflammatory markers signal the brain through neuronal and humoral 
pathways. Essentially, inflammatory mediators activate neuronal pathways, 
including vagal afferents, spinal afferents and humoral pathways including 
sensory circumventricular organs. These interoceptive signals are integrated 
in the ‘viscero-sensory hubs’ within the brainstem including the raphe 
nuclei, with further relay to higher subcortical and cortical centres, evoking 
sickness behaviour including fatigue, malaise etc(Brydon et al., 2008; 
Critchley and Harrison, 2013; Harrison et al., 2009b; Strike et al., 2004). 
Brainstem raphe nuclei are highly connected with circumventricular organs 
and their proximity to the cerebral aqueduct make them vulnerable to 
inflammatory insults (Hornung, 2003; Howerton et al., 2014). Modulating 
peripheral inflammation has been known to increase expression of CNS 
cytokine mRNA in rodents, activate CNS microglia (measured using a 
translocator protein (TSPO) PET imaging ligand,  [11C]-PBR28) in live 
primates, and modulate glucose metabolism and BOLD response in regions 
associated with mood regulation in humans  (Hannestad et al., 2012a; 
Hannestad et al., 2012b; Harrison et al., 2009a; Skelly et al., 2013). While 
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raised circulating inflammatory markers have been found to be associated 
with depression, two studies that have explored the relationship between 
depression and microglial activation (measured using PET imaging of the 
TSPO) in humans have found conflicting results(Hannestad et al., 2013; 
Setiawan et al., 2015). Interestingly, both studies found no relationship 
between circulating inflammatory markers and TSPO binding suggesting that 
circulating inflammatory markers may not reflect central processes and to 
some extent, may be independent of microglial processes.  
Our findings add to a handful of other studies that have demonstrated an 
association between systemic inflammation and molecular substrates of 
behaviour, in particular the dopaminergic system in primates and humans 
(Capuron et al., 2012; Felger et al., 2013).  Serotonergic systems interact 
highly with dopaminergic systems it is likely that these systems interact and 
there are a number of intermediate steps that link circulating TNF to 
brainstem 5-HTT availability.  
The reduction in brainstem 5HTT availability following specific TNF 
inhibition, was at best, modest (average reduction - 9%  and 36% in the best 
case). The minimal effective dose for SSRIs produces a 5-HTT occupancy of 
around 70 to 80% measured using SPECT(Preskorn, 2012).  A recent meta-
analysis of antidepressant effects of anti-inflammatory agents found an 
effect size similar to those of conventional antidepressant agents (Kohler et 
al., 2014). While we found a significant reduction in BDI scores, it is unlikely 
that all of the variance in reduction in depression scores is mediated fully 
through changes in 5-HTT availability. Indeed, Raison et al noted that 
antidepressant effect was present in those who have not responded to 
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conventional antidepressants which block 5-HTT activity(Raison et al., 
2013).  
Our study had several limitations. We have assumed that the changes in the 
brain are a direct result of changes in circulating inflammatory markers. 
However, the relationship between serotonin and inflammation is thought to 
be bidirectional. In other words, central serotonin can have an effect on 
circulating inflammatory markers. For example, 5HT2A receptor activation 
has been known to suppress TNF-α induced inflammation with extraordinary 
potency (Yu et al., 2008). In addition, anecdotal evidence suggest that 
antidepressants that increase serotonergic neurotransmission have anti-
inflammatory and analgesic effects. Due to ethical concerns, we did not 
have a control subject group, when examining the effect of etanercept on 
5-HTT availability and the participants were not blind to the intervention. It 
should be noted that all patients were treated with a disease modifying 
agent (DMARD) prior to treatment with etanercept, and the pre-treatment 
level of 5-HTT is reflective of this. Our data suggest that specific TNF 
inhibition is associated with further reduction in 5-HTT availability. Our 
sample size was small, but grounded on power calculation based on our pilot 
study (Cavanagh et al., 2010). However, we may have been underpowered 
to detect correlations between other circulating inflammatory markers and 
5-HTT availability. We were not powered enough to explore the effects of a 
large number of covariates in the model. Nevertheless, our findings with 
these small numbers reflect non-trivial effects.  Vitally, we have replicated 
our findings in two independent samples, indicating the robustness of our 
findings.  
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We did not compare the 5-HTT and cytokine levels between healthy 
subjects and psoriasis patients, as this was not the primary aim of the study. 
The median cytokine levels were higher in the psoriasis population in 
general. Age, gender, circadian rhythm, food intake, exercise and stress can 
explain the variance in cytokine levels in health. While we controlled for 
the effect of age and gender and plasma was extracted at the same time of 
day, using the same protocol, our healthy group was older and also was 
comprised of menopausal women. Menopausal status has been associated 
with increase in cytokine levels (Pfeilschifter et al., 2002). This may 
account for the variance in cytokines in this population. 
We used SPECT to measure 5-HTT availability, due to ease of access to [123I] 
-beta-CIT and access to the 12-detector dedicated head SPECT unit 
(Neurofocus 900) equipped with high-resolution collimator with an in-slice 
and z-axis resolution of 7 mm full-width half-maximum. Although more 
selective and superior ligands for 5-HTT are available, the uptake of [123I]-
beta-CIT in the brainstem at 4 hours is a validated measure of 5-HTT 
availability(de Win et al., 2005b).  
In summary, we have shown a significant association between circulating 
TNF-α and central 5-HTT availability in two independent samples. Greater 
circulating TNF-α was associated with greater 5-HTT. Treatment with 
Etanercept was associated with a reduction in 5-HTT levels. Our findings 
give some evidence of the relationship between how inflammatory markers 
may directly affect substrates of the brain responsible for mood regulation. 
We provide additional evidence as to how these therapeutic agents may be 
useful in depression.  
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Table 1: Details of demographic and clinical measures 
 Healthy 
volunteers 
median 
(interquartile 
range) 
Pre-treatment 
median 
(interquartile 
range) 
Post-
treatment 
median 
(interquartile 
range) 
Z* p * 
(FDR 
correct
ed p) 
r 
Age 
(mean/s.d.) 
57 (5.22) 47.58 (8.88)     
Gender 
n of 
females(%) 
13 (100) 6(50%)     
5-HTT 1.05(0.2) 1.10(0.2) 1.00(0.3) -2.09 .03 
(0.04) 
0.60 
TNF 
(pg/ml) 
3.8 (3.65) 12.75(83.56) 248.87(273.3
4) 
-2.70 .007 
(0.02) 
0.77 
IL1B 
(pg/ml) 
3.2 (5.35) 3.39(5.52) 7.29(9.51) -1.37 .16 
(0.18) 
0.39 
sIL2R (pg/ml) 2.3 (1.15) 4.6(2.23) 4.7(1.2) -0.05 0.9 
(0.9) 
0.01 
CRP 
(mg/ml) 
1.78 (2.17) 3.90(9.2) 3.26(5.57) -2.59 .009 
(0.02) 
0.75 
IL6 
(pg/ml) 
not available 2.84(5.41) 1.79(2.17) -2.36 .01 
(0.02) 
0.68 
BDI 8 (5) 10 (11.75) 5 (6.75) -2.2 .02  
(0.03) 
0.63 
*Wilcoxon Signed-ranks test exploring the difference between variables pre and 
post etanercept; r = effect size calculated as Z/√n; FDR - False discovery rate 
corrected probability for 7 comparisons. 
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Figure 1: Study design. a) healthy subjects ; b) psoriasis/psoriatic arthritis 
subjects 
 
Figure 2: Scatterplot showing the spearman's rank correlation between 
circulating inflammatory markers and brainstem 5-HTT availability. 
Scatterplot a,b,c and d show the relationship in healthy individuals. Only 
the relationship between TNF and 5-HTT in reached statistical significance 
(rho=0.61; p=0.03).5HTT was corrected for age; . Scatterplot e, f, g, h and i 
show the association between circulating inflammatory markers and 
brainstem 5-HTT in psoriasis/psoriatic arthritis. Only the relationship 
between TNF-α and 5-HTT reached statistical significance (rho=0.76; 
p=0.004). 5HTT corrected for age, sex and diagnosis.  Dotted lines depict 
95% confidence intervals.  
 
Figure 3: Indirect effects analysis shows that 5-HTT mediates the 
association between TNF-α and BDI scores in the whole sample (n=25). The 
mediation analysis partitions the total variance (total effect - c) explained 
by the predictor into a part that is independent of the mediating variable 
(direct effect - c'), and a part that is accounted for via the mediating 
variable (indirect effect - a*b). a represents the ‘a’ path and b represents 
the ‘b’ path. 
Figure 4: A representative scan (sagittal image) of a patient showing [123I] –
beta-CIT uptake at 4 hours in the brainstem (arrows)  – before (top row) and 
after (bottom row) treatment with Etanercept.  
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Highlights 
• Preclinical studies have found that cytokines affect 5HTT availability. 
• In humans, circulating TNF-α correlated with brainstem 5HTT availability. 
• Specific TNF antagonism was associated with reduction in 5HTT availability. 
 
 
